Long-term Follow-up Confirms Safety of Imatinib Discontinuation in CML

Share this content:
Physicians can safely discontinue imatinib in patients with CML with a sustained deep molecular response.
Physicians can safely discontinue imatinib in patients with CML with a sustained deep molecular response.

Physicians can safely discontinue imatinib in patients with chronic myeloid leukemia (CML) who have achieved a sustained deep molecular response, according to updated results from a study published in the Journal of Clinical Oncology.1

Tyrosine kinase inhibitor (TKI) therapy induces deep molecular responses in most patients with CML in chronic phase, and those patients have a low risk of progression and a high rate of long-term survival. Several discontinuation clinical trials demonstrate that patients with sustained deep molecular responses can safety discontinue TKI treatment and achieve treatment-free remission.

Researchers designed the STIM1 trial (Evaluation of the Persistence of the Complete Molecular Remission After Stopping Imatinib Chronic Myeloid Leukemia; ClinicalTrials.gov Identifier: NCT00478985) to evaluate the impact of imatinib discontinuation in patients who have had undetectable minimal residual disease for at least 2 years. Preliminary results demonstrated that nearly 40% of patients maintained a molecular remission following treatment discontinuation despite persistent low levels of leukemic cells.

After a median follow-up of 77 months after imatinib discontinuation, investigators found that molecular recurrence-free survival was 43% (95% CI, 33-52) at 6 months and 38% (95% CI, 29-47) at 60 months among the 100 patients evaluated.

Sixty-one patients lost undetectable minimal residual disease after a median of 2.5 months and 1 patient with undetectable minimal residual disease died at 10 months post-treatment discontinuation.

Investigators restarted imatinib treatment in 57 of those 61 patients with molecular recurrence, and 55 achieved a second deep molecular response within a median of 4 months.

RELATED: Prolonged Imatinib Therapy Linked With Deeper Molecular Response in CML-CP

No patients with CML in chronic phase experienced progression to accelerated or blast phase.

Imatinib treatment duration longer than 54 months and a low or intermediate Sokal risk score were associated with a lower risk of molecular recurrence.                        

Reference

  1. Etienne G, Guilhot J, Rea D, et al. Long-Term follow-up of the French Stop Imatinib (STIM1) study in patients with chronic myeloid leukemia. J Clin Oncol. 2016 Oct 3. doi: 10.1200/JCO.2016.68.2914 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters